

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
March 9, 2023

**Draft MEETING ROSTER**

---

---

**DESIGNATED FEDERAL OFFICER (Non-Voting)**

**She-Chia Jankowski, PharmD**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Mark R. Conaway, PhD**

Professor  
Division of Translational Research and Applied  
Statistics  
Department of Public Health Sciences  
University of Virginia  
Charlottesville, Virginia

**Jorge A. Garcia, MD, FACP**

*(Chairperson)*  
Chief, Division of Solid Tumor Oncology  
George & Edith Richman Distinguished Scientist Chair  
Professor of Medicine and Urology  
GU Medical Oncology Program  
University Hospitals Seidman Cancer Center  
Case Comprehensive Cancer Center  
Case Western Reserve University  
Cleveland, Ohio

**Ravi A. Madan, MD**

Senior Clinician, Genitourinary Malignancies Branch  
Head, Prostate Cancer Clinical Research Section  
Program Director, Physician-Scientist Early  
Investigator Program  
Center for Cancer Research  
National Cancer Institute, National Institutes of Health  
Bethesda, Maryland

**Anthony D. Sung, MD**

Associate Professor of Medicine  
Duke University School of Medicine  
Duke Adult Blood and Marrow Transplant Clinic  
Durham, North Carolina

**Neil Vasan, MD, PhD**

Assistant Professor  
Division of Hematology & Oncology  
Department of Medicine  
Herbert Irving Comprehensive Cancer Center  
Columbia University Medical Center  
New York, New York

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)**

**Jonathan D. Cheng, MD**

*(Industry Representative)*  
Head of Oncology Development  
Global Drug Development  
Bristol-Myers Squibb  
Lawrenceville, New Jersey

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
March 9, 2023

**Draft MEETING ROSTER (cont.)**

---

---

**TEMPORARY MEMBERS (Voting)**

**Christopher S. Coffey, PhD, MS**

Christopher S. Coffey, PhD  
Professor, Department of Biostatistics  
Director, Clinical Trials Statistical & Data  
Management Center  
University of Iowa  
Iowa City, Iowa

**Louis F. Diehl, MD**

Professor of Medicine  
Duke University  
Durham, North Carolina

**Kieron M. Dunleavy, MD**

Director of Hematology  
Lombardi Comprehensive Cancer Center  
Professor of Medicine  
Georgetown University  
Washington, District of Columbia

**Sandra Finestone, PsyD**

*(Acting Consumer Representative)*  
Association of Cancer Patient Educators  
Irvine, California

**Paul V. Majkowski, Esq.**

*(Patient Representative)*  
Albertson, New York

**Grzegorz (Greg) S. Nowakowski MD**

Professor of Medicine and Oncology  
Deputy Director for Clinical Research  
Mayo Clinic Comprehensive Cancer Center  
Rochester, Minnesota

**Manjunath (Amit) Pai, PharmD, FCP**

Professor and Chair  
Department of Clinical Pharmacy  
Co-Director of the PK Core  
College of Pharmacy  
University of Michigan, Ann Arbor  
Ann Arbor, Michigan

**Mikael A. Sekeres, MD, MS**

Mikael A. Sekeres, M.D., M.S.  
Professor of Medicine  
Chief, Division of Hematology  
Sylvester cancer Center  
University of Miami  
Miami, Florida

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
March 9, 2023

**Draft MEETING ROSTER (cont.)**

---

---

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

Director, Oncology Center of Excellence (OCE)  
Director (Acting)  
Office of Oncologic Diseases (OOD)  
Office of New Drugs (OND), CDER, FDA

**Marc R. Theoret, MD**

Deputy Center Director, OCE  
Supervisory Associate Director (Acting)  
OOD, OND, CDER, FDA

**Nicole Gormley, MD**

Director  
Division of Hematologic Malignancies II (DHM II)  
OOD, OND, CDER, FDA

**Yvette Kasamon, MD**

Clinical Team Lead  
DHM II, OOD, OND, CDER, FDA

**Maryam Yazdy, MD**

Clinical Reviewer  
DHM II, OOD, OND, CDER, FDA